FIELD: pharmacology.
SUBSTANCE: small peptides are described, which are derivatives of cytokine, interleukin-4 (IL-4), capable of binding receptors of IL-4 and inhibiting activation of macrophages and thus preventing start of the inflammatory response. Besides, the invention relates to application of the specified peptides for manufacturing of a medicinal agent for treatment of various pathological conditions, where a significant role is played by IL-4.
EFFECT: invention expands arsenal of agents for treatment of various pathological conditions, in which a significant role is played by IL-4.
18 cl, 17 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY AND ANTIGENBINDING FRAGMENT (Fab), WHICH BINDS WITH HUMAN INTERFERON-γ, DNA FRAGMENTS CODING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT, CELL, TRANSFORMED BY DNA FRAGMENT, AND METHOD OF OBTAINING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2013 |
|
RU2539752C2 |
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| ANTIBODIES TO CANINE INTERLEUKIN-4 ALPHA RECEPTOR | 2016 |
|
RU2736732C2 |
| ANTI-PD-1 ANTIBODIES | 2015 |
|
RU2711141C2 |
| ANTIBODY AGAINST IL-4R AND APPLICATION THEREOF | 2018 |
|
RU2758091C1 |
| METHODS AND COMPOSITIONS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES TREATMENT | 2012 |
|
RU2639540C2 |
| ENHANCEMENT OF IMMUNE RESPONSES MEDIATED BY PROTEINS FUSED FROM ANTIBODY AND CYTOKINE BY METHOD OF COMBINED ADMINISTRATION OF ANGIOGENESIS INHIBITOR | 1999 |
|
RU2229305C2 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| IMMUNOGLOBULINS K HUMAN CD52 | 2010 |
|
RU2603743C2 |
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
